Q32 Bio to take Ho­mol­o­gy Med­i­cines’ Nas­daq spot to fund PhII tri­als in au­toim­mune, in­flam­ma­to­ry con­di­tions

The re­verse merg­ers are flow­ing. Q32 Bio will take Ho­mol­o­gy Med­i­cines’ place on the Nas­daq, the com­pa­nies said Thurs­day morn­ing, and the bi­o­log­ics mak­er ex­pects to have about $115 mil­lion at the time their deal clos­es, like­ly in the first quar­ter of 2024.

The Mass­a­chu­setts biotechs fol­low Lenz Ther­a­peu­tics and Graphite Bio in join­ing the re­verse merg­er train, which, by year’s end, is ex­pect­ed to board a few more pri­vate com­pa­nies look­ing to take the pub­lic list­ing and cash of a biotech that flamed out in the clin­ic or re­sort­ed to “strate­gic al­ter­na­tives” for some oth­er rea­son.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER